These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29143971)

  • 1. Industry Perspective on Biomarker Development and Qualification.
    Gerlach CV; Derzi M; Ramaiah SK; Vaidya VS
    Clin Pharmacol Ther; 2018 Jan; 103(1):27-31. PubMed ID: 29143971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Private company profiles.
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE23-8. PubMed ID: 12874973
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 4. Interview with John W. Kozarich, PhD. Interview by Vicki Glaser.
    Kozarich JW
    Assay Drug Dev Technol; 2013 Jun; 11(5):283-8. PubMed ID: 23772549
    [No Abstract]   [Full Text] [Related]  

  • 5. Barriers to Alzheimer disease drug discovery and development in the biotechnology industry.
    Altstiel LD
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S29-32. PubMed ID: 12070359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Driving drug discovery: the fundamental role of academic labs.
    Silber BM
    Sci Transl Med; 2010 May; 2(30):30cm16. PubMed ID: 20445199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ultimate model organism: progress in experimental medicine.
    Littman BH; Williams SA
    Nat Rev Drug Discov; 2005 Aug; 4(8):631-8. PubMed ID: 16056389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving continuous manufacturing: technologies and approaches for synthesis, workup, and isolation of drug substance. May 20-21, 2014 Continuous Manufacturing Symposium.
    Baxendale IR; Braatz RD; Hodnett BK; Jensen KF; Johnson MD; Sharratt P; Sherlock JP; Florence AJ
    J Pharm Sci; 2015 Mar; 104(3):781-91. PubMed ID: 25470351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacometrics 2020.
    Gobburu JV
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):151S-157S. PubMed ID: 20881229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The difficulties industry is facing with investigators.
    Blackledge GR
    Eur J Cancer; 2005 Oct; 41(15):2210-2. PubMed ID: 16214043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of genomics in clinical trial design.
    Simon R
    Clin Cancer Res; 2008 Oct; 14(19):5984-93. PubMed ID: 18829477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The test of public scrutiny.
    Mallinckrodt CH
    Pharm Stat; 2006; 5(4):249-52. PubMed ID: 17219626
    [No Abstract]   [Full Text] [Related]  

  • 15. Barriers to Alzheimer disease drug discovery and drug development in the pharmaceutical industry.
    Anand R
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S33-9. PubMed ID: 12070360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-Generation Pharmaceutical Proteins-EUFEPS Workshop on Optimizing Biotech Medicines.
    Pasut G; Veronese FM
    IDrugs; 2007 Mar; 10(3):162-4. PubMed ID: 17351866
    [No Abstract]   [Full Text] [Related]  

  • 17. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The time is now.
    Nat Rev Drug Discov; 2005 Aug; 4(8):613. PubMed ID: 16106580
    [No Abstract]   [Full Text] [Related]  

  • 19. Medipol: the guardian angel of biologics.
    Laue C; Ruppanner V
    Nanomedicine (Lond); 2006 Aug; 1(2):251-4. PubMed ID: 17716114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
    Zabka TS; Burkhardt J; Reagan WJ; Gautier JC; Glaab WE; Guffroy M; Harding J; Brees D; McDuffie E; Ramaiah L; Schultze AE; Smith JD; Wolfreys A; Dalmas DA
    Regul Toxicol Pharmacol; 2021 Mar; 120():104857. PubMed ID: 33387566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.